Croda Commercial Launch Progressing as Expected
Zenakine commercial launch by Croda Beauty progressing as expected following April 2025 global launch.
vs expectations: in line
Select text to share a quote on X · sign in to keep highlights & notes in your SBTX notes
Commercial Launch Progressing as Expected
30 June 2025 - SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, reports that following the successful global launch of ZenakineTM by Croda Beauty in April 2025, the commercialisation of the product is progressing as expected by management.
According to the Croda Beauty website, Zenakine™ is being described as:
"…a cutting-edge neuroactive ingredient designed to counteract the effects of stress on the skin and improve overall wellbeing. It works in sync with the skin's natural biological rhythms, enhancing melatonin production to help improve sleep quality, elevating positive emotions and stimulating skin regeneration. It is the first ingredient with clinical instrumental measures on sleep quality and duration benefits."
SkinBioTherapeutics has had a long standing commercial and manufacturing agreement with Croda plc since 2019. As a result of the competitiveness of the global cosmetic industry, SkinBioTherapeutics is under a strict confidentiality agreement that prevents it from divulging information on sales or providing market forecasts.
In the meantime, management will be holding a presentation for investors about the recently signed commercial agreement with Superdrug on Thursday 3 July 2025 at 11am BST. For more information, please visit the Investor Meet Company link HERE.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.